Researchers compared sleep quality and biomarkers of neurodegeneration and cognitive scores between so-called poor sleepers and good sleepers with mild traumatic brain injury.
Study authors identified and evaluated a statistical signal for an increased risk of Guillain-Barré Syndrome in days 1-42 after 2018-2019 high-dose influenza vaccine administration.
Long-term survival analysis shows that patients with earlier initiation of sodium PB-TURSO treatment for ALS have longer median overall survival.
The eligibility criteria of the studies include: a maximum of 10 years having passed from the study publication, geographical diversity of the studies performed, and results pertaining both to animal models of AD, and to humans.
Participants in the multidisciplinary intervention group had significant improvements in verbal learning and memory, attention, cognitive flexibility, and processing speed.
A Phase 1 trial suggested that PD01A was safe and well tolerated over an extended period in patients with Parkinson disease.
The researchers found that 73.5 percent of the 737,839 community-dwelling beneficiaries with dementia were prescribed any CNS-active medication.
The FDA has approved Enspryng (satralizumab-mwge; Genentech) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
The FDA has granted accelerated approval to Viltepso for the treatment of DMD in patients who have a confirmed mutation of the DMD gene.
Individuals with severe periodontal disease or edentulism have an increased risk for incident dementia.
